Tumor-infiltrating lymphocytes: A predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5747-5754

  Heppner, Barbara Ingold ^a   Untch, Michael ^b   Denkert, Carsten ^a,c   Pfitzner, Berit M ^a   Lederer, Bianca ^d   Schmitt, Wolfgang ^a   Eidtmann, Holger ^e   Fasching, Peter A ^f   Tesch, Hans ^g   Solbach, Christine ^h   Rezai, Mahdi ⁱ   Zahm, Dirk M ^j   Holms, Frank ^k   Glados, Manfred ^l   Krabisch, Petra ^m   Heck, Esther ⁿ   Ober, Angelika ^o   Lorenz, Petra ^p   Diebold, Kurt ^q   Habeck, Jörg Olaf ^r   Loibl, Sibylle ^d   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d German Breast Group (GBG Forschungs GmbH)   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Bethanien Krankenhaus Frankfurt   (Germany)

^h Klinik für Frauenheilkunde und Geburtshilfe   (Germany)

ⁱ Luisenkrankenhaus Düsseldorf   (Germany)

^j Brustzentrum   (Germany)

^k St Barbara Klinik   (Germany)

^l Onkologische Gemeinschaftspraxis   (Germany)

^m KLINIKUM CHEMNITZ   (Germany)

ⁿ JOHANNA ETIENNE KRANKENHAUS   (Germany)

^o St Vincenz Krankenhaus   (Germany)

^p Institut für Pathologie   (Germany)

^q St Barbara Klinik   (Germany)

^r Zentrum für Histopathologie Chemnitz   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; GENE AMPLIFICATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; LYMPH NODE METASTASIS; LYMPHOCYTE PREDOMINANT BREAST CANCER; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PATHOLOGIC COMPLETE RESPONSE; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; LYMPHOCYTE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY;

BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85006293389     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2338     Document Type: Article

References (32)

1. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
2. Denkert C. The immunogenicity of breast cancer-molecular subtypes matter. Ann Oncol 2014;25:1453-5.
3. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol 2010;28: 2024-31.
4. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study. J Clin Oncol 2010;28:2015-23.
5. von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro). Ann Oncol 2014;25:81-9.
6. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011;22: 301-6.
7. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial. Lancet Oncol 2012;13:135-44.
8. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PloS ONE 2013;8:e79775.
9. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28: 105-13.
10. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31: 860-7.
11. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 2014;25:1544-50.
12. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials:ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32:2959-66.
13. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without Carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015;33:983-91.
14. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68.
15. Hudis CA.Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
16. Bianchini G,Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014;15:e58-68.
17. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-70.
18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6: 443-6.
19. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011;108:7142-7.
20. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized antip185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
21. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
22. Hannesdottir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 2013;43:2718-29.
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
24. Wolff AC,HammondME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
25. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26:259-71.
26. Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial. JAMA Oncol 2015;1:448-54.
27. Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2016;34:542-9.
28. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1183-92.
29. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, LiuMC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
30. Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of stromal tumor-infiltrating lymphocyteswith recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol 2016;2:56-64.
31. Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol 2016;13:228-41.
32. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80